| Literature DB >> 26219316 |
Urvashi Tiwari1, Shukla Das2, Mukta Tandon1, V G Ramachandran1, Rumpa Saha1.
Abstract
High morbidity and mortality caused by mycotic infections has been a cause for concern. Trials for various vaccines against fungal pathogens have not been approved by the US Food and Drugs Administration because of the high cost of production and lack of a single suitable candidate. Most fungal infections require cell-mediated immunity for their clearance. This has been the basis for the development of various vaccines. We discuss the various trials of candidate vaccines, the protective efficacy as well as their shortcomings. Recent research suggests that a universal vaccine can be prepared which may be effective against most fungal pathogens. Copyright 2015, NMJI.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26219316
Source DB: PubMed Journal: Natl Med J India ISSN: 0970-258X Impact factor: 0.537